Preview

Медицинский Совет

Расширенный поиск

Дабигатрана этексилат в профилактике кардиоэмболических осложнений у больных с неклапанной фибрилляцией предсердий

https://doi.org/10.21518/2079-701X-2014-12-33-39

Полный текст:

Аннотация

Кардиоэмболические осложнения - ишемический инсульт и тромбоэмболии не в сосуды центральной нервной системы - одно из наиболее тяжелых последствий фибрилляции предсердий (ФП) [1, 2]. Наиболее действенным способом их предотвращения является длительное (неопределенно долгое) использование антикоагулянтов, которые, по современным представлениям, показаны больным с ФП, имеющим дополнительные факторы риска сердечно-сосудистых осложнений.

Об авторе

И. С. Явелов
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, Москва
Россия


Список литературы

1. Guidelines for the management of atrial fibrillation.The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010, 31: 2369-2429.

2. Fuster V., Ryden L., Cannom D. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation, 2006, 114: e257-e354.

3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med, 1999, 131: 492-501.

4. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med, 2007, 146: 857-867.

5. Connolly S.J., Eikelboom J., Joyner C., et al., for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011, 364: 806-817.

6. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, 367: 1903-1912.

7. Hohnloser S.H., Pajitnev D., Pogue J., et al., for the ACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. JACC, 2007, 50: 2156-2161.

8. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper. JACC, 2012, 59: 1413-1425.

9. Lip GYH, Larsen TB, Skj0th Fl, Rasmussen LH. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. JACC, 2012, 60: doi:10.1016/j.jacc.2012.03.019

10. Connolly SJ, Connolly SJ, Ezekowitz MD et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361: 1139-1351.

11. Patel MR, Mahaffey KW, Garg J et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med, 2011, 365: 883-891.

12. Granger CB, Alexander JH, McMurray JJ et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981-992.

13. Connolly SJ, Wallentin L, Ezekowitz MD et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, 2013, 128: 237-243.

14. Nieuwlaat R, Healey JS, Ezekowitz M et al. Management of dyspepsia symptoms on dabigatran during RELY-ABLE: long-term follow up study after RE-LY. Eur Heart J, 2013, 34 (suppl. 1): doi: 10.1093/eurheartj/eht307.P549.

15. Eikelboom JW, Connolly SJ, Hart RG et al. Balancing the benefits and risks of two doses of Dabigatran compared with Warfarin in Atrial Fibrillation. JACC, 2013. DOI: 10.1016/j.jacc.2013.05.042.

16. Oldgren J, Alings M, Darius H et al. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Ann Intern Med, 2011, 155: 660-667.

17. Wallentin L, Yusuf S, Ezekowitz MD et al., on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 2010, DOI:10.1016/S0140-6736(10)61194-4.


Просмотров: 68


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)